ImmunityBio, Inc.
ImmunityBio Reports Increased Sales and Regulatory Updates for ANKTIVA
Summary
ImmunityBio, Inc. announced significant sales growth for its immunotherapy product ANKTIVA following the issuance of a permanent J-code in January 2025, which boosted unit sales by 97% in February 2025 compared to December 2024. The company also reported FDA authorization for expanded access to recombinant BCG to address BCG shortages, acceptance of global marketing authorization applications for ANKTIVA, and Regenerative Medicine Advanced Therapy designation by the FDA for ANKTIVA in combination with PD-L1 t-haNK. Financial results showed an increase in net product revenue to $7.2 million for the three-month period ending December 31, 2024, with overall net loss for the year at $413.6 million.
Profitelligence Alerts
Get alerts for IBRX
Be first to know when ImmunityBio, Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About ImmunityBio, Inc.
ImmunityBio, Inc. is a pioneering biotechnology company that focuses on developing innovative immunotherapies to treat cancer and other serious diseases. The company's primary function is to leverage the body's immune system to fight against various forms of cancer as well as infectious diseases through a robust pipeline of therapies. ImmunityBio's notable features include its expansive portfolio of next-generation therapies that incorporate cutting-edge technologies, such as the NANT Cancer Vaccine and Anktiva, which are designed to enhance the immune system's natural ability to identify and eradicate tumor cells. The company plays a critical role in the healthcare and biotechnology sectors, contributing to advancements in personalized medicine and potentially transformative treatments. Headquartered in California, ImmunityBio is strategically placed in the biotechnology hub of the United States, allowing it to effectively collaborate with key players in research and clinical development. Its work is significant in the market as it represents the ongoing shift towards immunotherapy as a front-line treatment for cancer, promising to impact patient outcomes and the future of cancer care.
Official SEC Documents
Advertisement